Abstract
Background
Methods
Results
Conclusions
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineReferences
- Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction a population-based perspective.Circulation. 2009; 119: 1211-1219
- Trends in incidence, management, and outcomes of cardiogenic shock complicating ST-elevation myocardial infarction in the United States.J Am Heart Assoc. 2014; 3 (e000590)
- Temporal trends and outcomes of patients undergoing percutaneous coronary interventions for cardiogenic shock in the setting of acute myocardial infarction: a report from the cathpci registry.JACC Cardiovasc Interv. 2016; 9: 341-351
- Cardiogenic shock complicating acute myocardial infarction: Expanding the paradigm.Circulation. 2003; 107: 2998-3002
- Shock in acute myocardial infarction: The Cape Horn for trials?.Eur Heart J. 2010; 31: 1828-1835
- Diabetes mellitus and cardiogenic shock in acute myocardial infarction.Eur J Heart Fail. 2005; 7: 834-839
- Overview of the National (Nationwide) Inpatient Sample (NIS).(Agency for Healthcare Research and Quality, Rockville, MD; Available at)https://www.hcup-us.ahrq.gov/nisoverview.jspDate accessed: January 12, 2018
- Trend Weights for HCUP NIS Data.(Agency for Healthcare Research and Quality, Rockville, MD; Available at)https://www.hcup-us.ahrq.gov/db/nation/nis/trendwghts.jspDate accessed: June 2, 2017
- Adaptation of AHRQ patient safety indicators for use in ICD-10 administrative data by an international consortium.in: Advances in Patient Safety: New Directions and Alternative Approaches. Vol. 1: Assessment. Agency for Healthcare Research and Quality, Rockville, MD2008: 1-19
- Evaluation of care and surveillance of cardiovascular disease: can we trust medico-administrative hospital data?.Can J Cardiol. 2012; 28: 162-168
- Trends in management and outcomes of ST-elevation myocardial infarction in patients with end-stage renal disease in the United States.Am J Cardiol. 2015; 115: 1033-1041
- Smoker's paradox in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.J Am Heart Assoc. 2016; 5 (e003370)
- HCUP CCS.(Agency for Healthcare Research and Quality, Rockville, MD; Available at) (Accessed January 12, 2018)
- Systematic review of validated case definitions for diabetes in ICD-9-coded and ICD-10-coded data in adult populations.BMJ Open. 2016; 6 (e009952)
- Comorbidity measures for use with administrative data.Med Care. 1998; 36: 8-27
- Adherence to methodological standards in research using the National Inpatient Sample.JAMA. 2017; 318: 2011-2018
- Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding.BMJ. 2005; 330: 960-962
- Outcomes of medicare beneficiaries with heart failure and atrial fibrillation.JACC Heart Fail. 2014; 2: 41-48
- Relationship between early physician follow-up and 30-day readmission among medicare beneficiaries hospitalized for heart failure.JAMA. 2010; 303: 1716-1722
- Diabetes mellitus in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry.J Am Coll Cardiol. 2000; 36: 1097-1103
- Effect of diabetes on the mortality risk of cardiogenic shock in a community-based population.Mayo Clin Proc. 2003; 78: 561-566
- Outcomes in patients with cardiogenic shock following percutaneous coronary intervention in the contemporary era: an analysis from the BCIS database (British Cardiovascular Intervention Society).JACC Cardiovasc Interv. 2014; 7: 1374-1385
- The influence of diabetes on in-hospital and long-term mortality in patients with myocardial infarction complicated by cardiogenic shock: results from the PL-ACS registry.Kardiol Pol. 2012; 70: 1215-1224
- Prognostic value of admission blood glucose level in patients with and without diabetes mellitus who sustain ST segment elevation myocardial infarction complicated by cardiogenic shock.Crit Care. 2013; 17: R218
- Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention.Circulation. 2011; 124: 704-711
- The changing face of diabetes complications.Lancet Diabetes Endocrinol. 2016; 4: 537-547
- Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy.Am Heart J. 2007; 154: 743-750
- Arrhythmia susceptibility and myocardial composition in diabetes. Influence of physical conditioning.J Clin Invest. 1986; 77: 382-395
- Increased prevalence of ventricular fibrillation in patients with type 2 diabetes mellitus.Heart Vessels. 2007; 22: 251-253
- Diabetic autonomic neuropathy.Diabetes Care. 2003; 26: 1553-1579
- Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study).Am J Cardiol. 2000; 86: 309-312
- Heart rate variability and heart rate turbulence in patients with type 2 diabetes mellitus with versus without cardiac autonomic neuropathy.Am J Cardiol. 2007; 100: 890-893
- Association between hyperglycemia and the no-reflow phenomenon in patients with acute myocardial infarction.J Am Coll Cardiol. 2003; 41: 1-7
- Differences in the profile, treatment, and prognosis of patients with cardiogenic shock by myocardial infarction classification a report from NCDR.Circ Cardiovasc Qual Outcomes. 2013; 6: 708-715
- Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction.JAMA. 2006; 295: 2511-2515
- Prevalence of and trends in diabetes among adults in the United States, 1988-2012.JAMA. 2015; 314: 1021-1029
- Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction (DIGAMI).Circulation. 1999; 99: 2626-2632
Article info
Publication history
Footnotes
Funding: None.
Conflicts of Interest: GCF reports significant consulting for Novartis, and modest consulting for Amgen, Medtronic, and Janssen; he holds the Eliot Corday Chair of Cardiovascular Medicine at UCLA and is also supported by the Ahmanson Foundation (Los Angeles, California). DLB discloses the following relationships—Advisory Board: Cardax, Elsevier Practice Update Cardiology, Medscape Cardiology, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Cleveland Clinic, Duke Clinical Research Institute, Harvard Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine, Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, ACC.org), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees), Harvard Clinical Research Institute (clinical trial steering committee), HMP Communications (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Population Health Research Institute (clinical trial steering committee), Slack Publications (Chief Medical Editor, Cardiology Today's Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Amarin, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Ironwood, Ischemix, Lilly, Medtronic, Pfizer, Roche, Sanofi Aventis, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald's Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, St. Jude Medical (now Abbott); and Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, PLx Pharma, Takeda.
All the other authors have nothing to disclose.
Authorship: All authors had access to the data, participated in the research and preparation of the manuscript.
